Sanofi makes huge investment in the future of biologics
19 April 2016 | By Mandy Parrett, Editorial Assistant
Sanofi has announced plans to invest €300 million to expand its manufacturing and commercial capabilities at its site in Geel, Belgium.
List view / Grid view
News
ProStrakan rebrands as Kyowa Kirin International PLC
Kyowa Hakko Kirin (KHK), the company that acquired ProStraken in 2011, has decided that its western pharmaceutical subsidiaries are to adopt the Kyowa Kirin name...
Jardiance to be investigated in chronic heart failure trials
19 April 2016 | By Victoria White, Digital Content Producer
Boehringer Ingelheim and Lilly have announced plans to conduct two trials investigating Jardiance for the treatment of people with chronic heart failure...
Tecfidera demonstrates sustained efficacy in RRMS studies
18 April 2016 | By Victoria White, Digital Content Producer
Biogen has unveiled new Tecfidera research that reinforces its sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis patients...
Opdivo and Yervoy combination demonstrates superior efficacy in melanoma study
18 April 2016 | By Victoria White, Digital Content Producer
A Opdivo and Yervoy combination regimen demonstrated a two-year OS rate of 69% compared to 53% for Yervoy alone in BRAF wild-type advanced melanoma...
AbbVie presents data for ABT-493 and ABT-530 regimen in HCV
18 April 2016 | By Victoria White, Digital Content Producer
With eight weeks of treatment, 97-98 percent of GT1-3 HCV infected patients without cirrhosis treated with ABT-493 and ABT-530 achieved sustained SVR12...
NICE recommends ataluren for Duchenne muscular dystrophy
18 April 2016 | By Victoria White, Digital Content Producer
NICE has recommended Translarna (ataluren) for treating children aged 5 and over with Duchenne muscular dystrophy caused by a nonsense mutation...
Gilead announces results from two Phase III studies of TAF in HBV
15 April 2016 | By Victoria White, Digital Content Producer
Studies 108 and 110 were 48-week clinical trials evaluating TAF among 1,298 treatment-naïve and treatment-experienced patients with chronic HBV infection...
AstraZeneca reports new data for osimertinib in NSCLC
15 April 2016 | By Victoria White, Digital Content Producer
AstraZeneca has reported new Phase I extended follow-up data on osimertinib in both first- and second-line treatment of patients with non-small cell lung cancer (NSCLC).
Global viral infections market to hit $117.6 billion by 2021, says GBI Research
15 April 2016 | By Victoria White, Digital Content Producer
The global viral infections market will grow from $74 billion in 2014 to $117.6 billion by 2021, according to business intelligence provider GBI Research...
AbbVie presents real-world data for Viekirax + Exviera in HCV
15 April 2016 | By Victoria White, Digital Content Producer
AbbVie has announced new real-world data for Viekirax and Exviera, showing 96% of GT1 HCV patients and 100% of GT4 patients achieved SVR12...
FDA accepts sBLA for Opdivo in classical Hodgkin Lymphoma
15 April 2016 | By Victoria White, Digital Content Producer
The FDA has accepted a sBLA for Opdivo that seeks to expand the use of the therapy to patients with Hodgkin Lymphoma after prior therapies...
Immunotherapy plus live bacterium shows promise in malignant pleural mesothelioma
14 April 2016 | By Victoria White, Digital Content Producer
Immunotherapy with a live bacterium combined with chemotherapy demonstrated more than 90% disease control and 59% response rate in malignant pleural mesothelioma...
Positive results for AbbVie’s Viekirax + Exviera regimen
14 April 2016 | By Victoria White, Digital Content Producer
AbbVie announced high SVR sates with Viekirax + Exviera regardless of the presence of resistance-associated variants prior to treatment in GT1 chronic HCV patients...
EC approves Opdivo in NSCLC and advanced kidney cancer
14 April 2016 | By Victoria White, Digital Content Producer
The EC has granted approval for the use of Opdivo (nivolumab) to treat patients with the most common forms of advanced lung and advanced kidney cancer...
